Eisai, Arena to launch obesity drug next month

05/9/2013 | PharmaTimes (U.K.)

Eisai and Arena Pharmaceuticals plan to launch their antiobesity drug Belviq, or lorcaserin, in the U.S. next month following the drug's classification as a Schedule IV controlled substance. Belviq was approved by the FDA last year for chronic weight management in obese adults who suffer from at least one weight-related condition. The launch triggers the payment of a $65 million milestone fee from Eisai to Arena.

View Full Article in:

PharmaTimes (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Director, Site Quality Management
CareFusion
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC